Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine's controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label...

Avexa Reports Positive Phase IIb Result

...AVX) today announced highly successful results from its Phase IIb trial for apricitabine (ATC). ATC is Avexa's novel nucleoside reverse transcriptase inhibitor (NRT...or antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Ph...

Apricitabine in Biological Technology

Progen Concedes Shareholder Requisitioned Meeting

... Phase III trials and no partnering deal eventuated. The Avexa merger proposes to focus investment in the Phase III trials of apricitabine (ATC). -- ATC has also not been partnered and the total estimated cost of completion of Phase III trials is $155 million. In the ...

Cytopia and Other Progen Shareholders Maintain Call for Meeting

...the proposed merger, shareholders would effectively become investors in an HIV company with long and costly funding requirements in HIV drug candidate apricitabine (ATC). The shareholder proposal offers the choice of either staying as investors in a cancer focused biotech company or redeeming the cash backin...

Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts

...and development programs. Avexa plans to use Monogram's assays across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase...